Antengene Corporation closes USD97m Series C round for new drug

Antengene Corporation, a leading innovative hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies, recently announced the completion of a Series C round of financing, raising 97 million US dollars.

Antengene Corporation, a leading innovative hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies, recently announced the completion of a Series C round of financing, raising 97 million US dollars.

The round was led by Fidelity Management & Research Company LLC with additional support from new investors including GL Ventures, GIC, and a large, reputable long-term investor.

Existing investors including Qiming Venture Partners and Boyu Capital also participated.

Proceeds from the latest round will be used primarily to consolidate and strengthen the company’s robust research and development pipeline, advance the continued clinical development of its hematology oncology and solid tumor products, continue to expand the in-house research and development capabilities of its early-stage drugs, and further strengthen the company’s commercialization capabilities in the Asia-Pacific market.

Currently, Antengene has established an extensive R&D pipeline covering six clinical-stage products and six pre-clinical stage projects, and has made several significant advances.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/23/antengene-corporation-closes-usd97m-series-c-round-for-new-drug/.

Leave a Reply

Please Login to Comment